Topical and systemic formulation options for cutaneous T cell lymphomas

Taku Fujimura; Ryo Amagai; Yumi Kambayashi; Setsuya Aiba

doi:10.3390/pharmaceutics13020200

Topical and systemic formulation options for cutaneous T cell lymphomas

Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Setsuya Aiba

Tohoku University

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early-and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

Original language	English
Article number	200
Pages (from-to)	1-14
Number of pages	14
Journal	Pharmaceutics
Volume	13
Issue number	2
DOIs	https://doi.org/10.3390/pharmaceutics13020200
Publication status	Published - 2021 Feb

Keywords

Bexarotene
CTCL
HDAC inhibitors
Interferon
Targeted therapy
Topical formulation

Access to Document

10.3390/pharmaceutics13020200

Cite this

@article{87ec90c5c1af4c3f81ceb141bf7328be,

title = "Topical and systemic formulation options for cutaneous T cell lymphomas",

abstract = "Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early-and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.",

keywords = "Bexarotene, CTCL, HDAC inhibitors, Interferon, Targeted therapy, Topical formulation",

author = "Taku Fujimura and Ryo Amagai and Yumi Kambayashi and Setsuya Aiba",

note = "Funding Information: This study was supported, in part, by the Japan Agency for Medical Research and Development (Grant No. 18lm0203062h0001). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = feb,

doi = "10.3390/pharmaceutics13020200",

language = "English",

volume = "13",

pages = "1--14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Topical and systemic formulation options for cutaneous T cell lymphomas

AU - Fujimura, Taku

AU - Amagai, Ryo

AU - Kambayashi, Yumi

AU - Aiba, Setsuya

N1 - Funding Information: This study was supported, in part, by the Japan Agency for Medical Research and Development (Grant No. 18lm0203062h0001). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/2

Y1 - 2021/2

N2 - Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early-and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

AB - Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early-and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

KW - Bexarotene

KW - CTCL

KW - HDAC inhibitors

KW - Interferon

KW - Targeted therapy

KW - Topical formulation

UR - http://www.scopus.com/inward/record.url?scp=85100745985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100745985&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics13020200

DO - 10.3390/pharmaceutics13020200

M3 - Review article

AN - SCOPUS:85100745985

SN - 1999-4923

VL - 13

SP - 1

EP - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 200

ER -

Topical and systemic formulation options for cutaneous T cell lymphomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this